Manon Fiorot's Three-Month Suspension: In-Competition Ostarine Positive, Supplement Questions and Uncertainty in Women's Flyweight
ম্যানন ফিওরো তিন মাসের নিষেধাজ্ঞা মেনে নিয়েছেন। ইন-কম্পিটিশন নমুনায় নিষিদ্ধ ওস্টারিন পাওয়া গেছে। সাসপেনশন অক্টোবর ১৯ থেকে জানুয়ারি ১৯ পর্যন্ত; বছর উল্লেখ নেই। ইউএফসি বলেছে, তিনি পূর্ণ সহযোগিতা করেছেন। ফাইট উইকে পুষ্টিবিদের কাছ থেকে কয়েকটি সাপ্লিমেন্ট পেয়েছিলেন; ফাইট উইক শেষে বন্ধ করেছেন। প্রতিবেদনে পণ্যের নাম, ব্যাচ নম্বর, ল্যাবরেটরির বিস্তারিত, পরিমাণ, টেস্টিং কর্তৃপক্ষ, অ্যাপিলের শর্ত ও লড়ার কৌশলগত তথ্য নেই। ফলে উপসর্গের উৎস, ইচ্ছাকৃততা, পারফরম্যান্সে প্রভাব, বাণিজ্যিক ক্ষতি ও বর্তমান Status নির্ধারণ করা যায় না। সাপ্লিমেন্টের চেইন অফ কাস্টডি ও অফিসিয়াল কেস ডকুমেন্টেশনই মূল যাচাইযোগ্য প্রশ্ন।
Manon Fiorot, ranked in the women's flyweight division, received a three-month suspension after an in-competition sample tested positive for ostarine. The UFC said she accepted the ban and cooperated fully with investigators. The suspension ran from October 19 through January 19, though the year is not specified in the source report.

Fiorot said a nutritionist supplied several supplements during the week before the bout with Alexa Grasso, and that she stopped using them after fight week. The report does not identify the products, batch numbers, laboratory findings, concentration, testing authority, or appeal terms. It also gives no technical breakdown of the Grasso bout, no round-by-round statistics, no record, no method-of-victory data, and no injury or weight-cut history.
The case is an availability and compliance matter rather than a verdict on Fiorot's fighting ability. Her reported age is 36, and she was reported as ranked fourth in the women's flyweight division, but the ranking source and date are absent, so its current validity cannot be confirmed.

The chain of custody for fight-week supplements is the real story. If product names, batch numbers and independent batch-testing records were released, they would show how effective the controls around her camp were. Ostarine is a prohibited selective androgen receptor modulator (SARM), and a positive in-competition sample raises a traceability question that cannot be answered without those documents. "Low levels" is the UFC's characterization, not a laboratory measurement, and without a concentration figure and independent context, it cannot establish source, intent, or performance effect.
The three-month term does not explain itself. Cooperation and acceptance are reported, but the report does not state whether those factors affected the duration of the sanction. The testing agency, adjudication process, and the governing anti-doping policy are not named, so the case cannot support conclusions about UFC-wide enforcement consistency.
A suspension is an availability problem, not a technical verdict. Without a bout schedule, purse data, sponsorship information or event revenue, no commercial impact can be quantified. A ranked position may heighten interest, but it does not establish commercial draw or title-shot consequences.
The missing year is the most consequential gap. Suspension dates without a year prevent any assessment of whether the sanction is current or historical, whether a scheduled fight was moved, or whether her eligibility has since been restored. The full anti-doping decision and laboratory documentation would be needed to draw conclusions about intent, contamination, or performance effect.
Based on my years of watching matches and reporting on combat sports, a positive test is a compliance fact, not a technical one. The question that matters for the division is what happens next: whether official case documentation, product and batch information, and her next official bout announcement become public. If those documents surface, the narrative will shift from sanction to source. If they do not, the case will remain a narrow disciplinary record with an unanswerable question about the source of the positive result.

